TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04771572: Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Sponsor: Newave Pharmaceutical Inc · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$2,953,104

Rescue Site Savings

+$1,947,792

Unlock Full NCT04771572 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04771572 Rescue Dossier →